Results 41 to 50 of about 4,137,509 (275)

Development and research progress of anti-drug resistant fungal drugs

Journal of Infection and Public Health, 2022
With the widespread use of immunosuppressive agents and the increase in patients with severe infections, the incidence of fungal infections worldwide has increased year by year.
Xiangyi Cui, Lanlin Wang, Yuhong Lü, Changwu Yue   +3 more
doaj   +1 more source

Resistance to echinocandin-class antifungal drugs [PDF]

Drug Resistance Updates, 2007
Invasive fungal infections cause morbidity and mortality in severely ill patients, and limited drug classes restrict treatment choices. The echinocandin drugs are the first new class of antifungal compounds that target the fungal cell wall by blocking beta-1,3-d-glucan synthase.
openaire   +2 more sources

Engineering a Cysteine-Deficient Functional Candida albicans Cdr1 Molecule Reveals a Conserved Region at the Cytosolic Apex of ABCG Transporters Important for Correct Folding and Trafficking of Cdr1

mSphere, 2021
Overexpression of the fungal pleiotropic drug resistance (PDR) transporter Cdr1 is a major cause of antifungal drug resistance in Candida ...
Golnoush Madani, Erwin Lamping, Richard D. Cannon   +2 more
doaj   +1 more source

Cryptococcus flips its lid – membrane phospholipid asymmetry modulates antifungal drug resistance and virulence

, 2016
Human fungal infections are increasing in prevalence and acquisition of antifungal drug resistance, while our antifungal drug armamentarium remains very limited, constituting a significant public health problem. Despite the fact that prominent antifungal
David S. Perlin, Yina Wang, Erika Shor, Chaoyang Xue   +3 more
core   +1 more source

Candidemia : evolution of drug resistance and novel therapeutic approaches [PDF]

, 2021
Candidemia and invasive candidiasis are the most common healthcare-associated invasive fungal infections, with a crude mortality rate of 25-50%. Candida albicans remains the most frequent etiology, followed by C. glabrata, C.
Prigitano, Anna, Barchiesi, Francesco, Brescini, Lucia, Morroni, Gianluca, Tortorano, Anna Maria, Lucia Brescini, Anna Maria Tortorano, Anna Prigitano, Gianluca Morroni, Francesco Barchiesi   +9 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Deciphering the multidrug resistance paradigm in Candida auris

Antimicrobial Agents and Chemotherapy
Candida auris has garnered substantial clinical and public health attention for its widespread antifungal resistance. Most isolates are resistant to fluconazole, and many, to other drug classes, with acquired resistance to all clinically available ...
Darian J. Santana, Nicholas C. Cauldron, P. David Rogers, Christina A. Cuomo   +3 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

Molecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon   +9 more
wiley   +1 more source

Predicting the emergence of resistance to antifungal drugs [PDF]

FEMS Microbiology Letters, 2001
The emergence of antifungal drug resistance is inevitable. Here I discuss antibiotic resistance in the context of the adaptive potential of fungi and I propose an approach to predicting the evolution of antifungal resistance using experimental evolution of DNA sequences and microbial populations.
openaire   +2 more sources